Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.
Transcript:
I think I’ve said it before a couple times: access, access, access. We need to figure out better ways to ensure every patient with myeloma has access to this new generation of cellular immunotherapies, either direct or indirect cellular immunotherapies. Right now, they’re grossly limited to academic centers with lots of [resources and] expertise because of the cytokine release syndrome and other aspects that make them a little more challenging to give [to patients], at least initially.
To effect real change in the community, or at least where multiple myeloma is being taken care of, we [have to] strive to translate these assets into more community-friendly therapeutics.
Transcript edited for clarity.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.